George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.20
Bid: 136.80
Ask: 137.60
Change: 0.60 (0.44%)
Spread: 0.80 (0.585%)
Open: 141.80
High: 141.80
Low: 135.40
Prev. Close: 136.60
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

19 Jan 2023 07:00

RNS Number : 1883N
Elementis PLC
19 January 2023
 

Elementis plc

Trading Update

Full-year results in line with expectations; leverage reduction on track

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months and year ended 31 December 2022(1).

Business performance

 

The Group delivered a solid performance during the fourth quarter, despite experiencing weaker trading conditions as the macro-economic environment deteriorated through the period. Underlying operating profit for 2022 (including Discontinued Operations) is expected to be in the range $120-123m, in line with market expectations(2) and significantly ahead of the prior year.

 

· Coatings performed well, with pro-active pricing actions and product mix improvement offsetting weaker demand in European and Asian markets and customer destocking.

 

· Personal Care continued to perform strongly. In Cosmetics, pricing actions more than offset continuing cost inflation and some weakening of demand in certain regions. AP Actives demand remained robust.

 

· Talc performance remained materially below the prior year, due to continued volume weakness in its European markets, in particular automotive, and higher energy and logistics costs.

Balance Sheet

 

Net debt at the end of 2022 is anticipated to be approximately $367m (excluding lease liabilities), representing a leverage ratio of 2.2x net debt to EBITDA(3), down from 2.6x at the start of the year.

The sale of the Chromium business remains on track to complete during the first quarter of 2023 and to deliver net cash proceeds of approximately $107m, further reducing the Group's leverage ratio.

 

Preliminary full-year 2022 Results will be released on 7 March 2023.

 

 

Enquiries :

Elementis plc

David Boyd, Investor Relations Tel: +44 7764 905135

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

 

(1) Including the Chromium business which will be reported in 2022 as "Asset Held for Sale" and "Discontinued Operation".

(2) Based on company compiled consensus, the Board believes the average market forecast for 2022 adjusted operating profit (including Discontinued Operations) to be $121m.

(3) Excluding IFRS 16 impact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTMZGMMRRRGFZM
Date   Source Headline
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.